Kenneth Adea

Oct 29, 2024 | biorxiv.org | Meriem Bekliz |Manel Essaidi-Laziosi |Kenneth Adea |Krisztina Hosszu-Fellous

AbstractIn the 5th year after the emergence of SARS-CoV-2, Omicron lineages continue to evolve and cause infections. Here, we used eight authentic SARS-CoV-2 isolates to assess their capacity to escape immunity of different exposure histories and their replicative capacity in polarized human airway epithelial cells (HAE) derived from the nasal and bronchial epithelium.

Feb 15, 2024 | biorxiv.org | Meriem Bekliz |Manel Essaidi-Laziosi |Kenneth Adea |Krisztina Hosszu-Fellous

AbstractSince their emergence in late 2021, SARS-CoV-2 Omicron replaced earlier variants of concern and marked a new phase in the SARS-CoV-2 pandemic. Until the end of 2023, Omicron lineages continue to circulate and continue to evolve, with new lineages causing infection waves throughout 2022 and 2023.

Nov 29, 2023 | thelancet.com | Olha Puhach |Mathilde Bellon |Kenneth Adea |Meriem Bekliz

SummaryMucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2 is well understood, we have a limited understanding about the antibodies present on the nasal mucosal surfaces. In this study, we evaluated SARS-CoV-2 mucosal antibodies following previous infection, vaccination, or a combination of both.